Navigation Links
Peregrine Pharmaceuticals Reports Studies Published in 'Science' Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
Date:5/13/2008

development for the treatment of certain viral diseases and cancer. It is the first in a new class of targeted anti-PS immunotherapeutics that binds to phosphatidylserine, a specific component of certain cellular membranes. PS is normally present only on the inside of cell membranes, but becomes exposed on the external surface of enveloped viruses and the cells they infect. Enveloped viruses are responsible for about half of all human viral diseases, including HCV, influenza, HIV, cytomegalovirus and other virus strains. Scientists believe that bavituximab helps block the ability of viruses to infect cells and also helps stimulate the body's natural immune defenses to destroy both the virus particles and infected cells. Since the PS targeted by bavituximab is primarily exposed on diseased cells, healthy cells should not be affected.

In preclinical studies, bavituximab has demonstrated the ability to bind to a wide range of enveloped viruses and virally infected cells and has shown promising activity in animal models of serious viral diseases. Bavituximab appeared well tolerated with no dose limiting adverse events and showed encouraging signs of antiviral activity as monotherapy in two Phase I trials in patients with chronic hepatitis C viral infection. A clinical trial in patients co-infected with HCV and HIV is now underway, and additional studies in HCV patients are planned. Similar to their proposed anti-viral mechanism, anti-PS antibodies also bind to phosphatidylserine exposed on tumor blood vessels in all solid cancers tested to date. Bavituximab demonstrated promising signs of anti-tumor activity in a Phase l trial in combination with chemotherapy in patients with advanced solid tumors, and Phase II cancer trials are underway.

1. Vaccinia Virus Uses Macropinocytosis and Apoptotic Mimicry to Enter Host Cells, Jason Mercer and Ari Helenius* Science 25 April 2008: Vol. 320. no. 5875, pp. 531 - 535

2. Role of C. elegans TAT-1 Protein in Main
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
2. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
3. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
4. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
6. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
8. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
9. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
10. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
11. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... York , September 23, 2014 ... leading provider of  Closed System Transfer     Devices ... exclusive partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s ... in Taiwan , ... as the company continues to expand globally, and ...
(Date:9/23/2014)... 23, 2014 Dr. Williams says, “Find ... on healthcare offers a three phase process that can ... delivery system that would go far beyond anything previously ... the delivery of healthcare.” , “Every effort to improve ... to provide discernable progress throughout that system because all ...
(Date:9/23/2014)... England , September 23, 2014 ... launched with funding from Imperial Innovations, Cambridge Innovation Capital ... Inivata, a clinical cancer genomics company focused on ... analysis to improve cancer testing and treatment, today ... round led by Imperial Innovations and including Cambridge ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , Sept. ... WBMD ), the leading source of health information, ... survey that provide novel insights regarding physician and ... and care.  Dr. Eric Topol , a leading ... who serves as both Editor-in-Chief of Medscape and Chief ...
Breaking Biology Technology:Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4
... Scheduled for Thursday, May 15th at 5 PM ... ... IMRX ) today announced that the Company has postponed its live,webcast and ... quarter 2008 financial results; this call was originally,scheduled for Tuesday, May 13, 2008, ...
... Interleukin Genetics,Inc. (Amex: ILI ) announced today that ... Rodman and Renshaw 5th Annual Global,Healthcare Conference on Monday ... The conference will be held at Le Meridien Beach ... of the presentation will be available on the,Investors section ...
... BETHLEHEM, Pa., May 13 Particle Sciences has expanded,its ... ft Class 1000 (ISO 6),clean room. The space also ... was added to the existing 15,000 sq ft facility ... manufacturing,especially that of semisolids, suspensions and dispersions. "This,investment is ...
Cached Biology Technology:Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:9/23/2014)... 2014 Research and Markets  has announced ... and Opportunities, 2019" report to their offering. ... enhancing security and protection in private as well as ... country,s government is focusing on using biometric systems to ... national IDs that are of crucial importance to the ...
(Date:9/23/2014)... CORAL SPRINGS, Florida , September 23, 2014 ... listings for innovative companies in tech sector position for significant ... generation products & services.  Companies in focus today are: NXT-ID, ... (NYSE: BABA ), Mobileye N.V. (NYSE: ... ReWalk Robotics Ltd. (NASDAQ: RWLK) NXT-ID, Inc. (NASDAQ: ...
(Date:9/23/2014)... have parasitic DNA fragments called "jumping genes" that insert ... process. And that phenomenon can result in age-related diseases ... Rochester now report that the "jumping genes" in mice ... protein stops keeping them in check in order to ... published today in Nature Communications , Professor of ...
Breaking Biology News(10 mins):India Biometrics Market Forecast and Opportunities, 2019 2India Biometrics Market Forecast and Opportunities, 2019 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7A multi-function protein is key to stopping genomic parasites from 'jumping' 2
... the 20th EORTCNCIAACR Symposium on "Molecular Targets and ... from Tuesday 21 October-Friday 24 October. Today ... accommodation via the official local agent if you ... the European Organisation for the Research and Treatment ...
... national trial of a catheter-based treatment for deep ... in combination with clot removal devices to prevent ... of a blood clot in a leg vein). ... permanent damage to the veins, resulting in debilitating ...
... Wayne State University have tested a breast cancer vaccine ... even cancers resistant to current anti-HER2 therapy - without ... 15 issue of Cancer Research, a journal ... vaccine could treat women with HER2-positive, treatment-resistant cancer or ...
Cached Biology News:Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 2Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs 3Vaccine against HER2-positive breast cancer offers complete protection in lab 2Vaccine against HER2-positive breast cancer offers complete protection in lab 3
... BacMagic™ DNA Kit provides a positive selection ... recombinant protein expression in insect cells. The ... generating recombinant baculoviruses by eliminating the time-consuming ... is an AcNPV genome with a portion ...
... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. ... Dim: surface area 500 cm 2 ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
Biology Products: